It is made available under a CC-BY-NC-ND 4.0 International license .

2 Long-Read Sequencing Increases Diagnostic Yield for Pediatric Sensorineural 3 **Hearing Loss** 4 5 Shelby E. Redfield¹, Wanging Shao², Tiegi Sun¹, Adrian Pastolero¹, William J. Rowell³, Courtney E. French², Cillian Nolan³, J. Matthew Holt³, Christopher T. Saunders³, Cairbre 6 Fanslow³, Eirini Maria Lampraki³, Christine Lambert³, Margaret Kenna^{1,2,4}, Michael 7 8 Eberle³, Shira Rockowitz^{2,5,6}, Aiden Eliot Shearer^{*1,2,4} 9 10 1. Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, 11 Boston, MA, USA, 12 2. Children's Rare Disease Collaborative, Department of Information Technology, Boston Children's 13 Hospital, Boston, MA, USA. 14 3. Pacific Biosciences, Menlo Park, CA, USA 15 Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA, USA. 16 5. Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, 17 MA. USA. 18 6. The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115. 19 *Corresponding Author: Eliot Shearer, eliot.shearer@childrens.harvard.edu 20 21

22

It is made available under a CC-BY-NC-ND 4.0 International license .

23 **ORCID**:

- 24 Shelby Redfield: 0000-0002-3485-6654
- 25 Wanging Shao: 0000-0003-4234-2095
- 26 Tieqi Sun: 0009-0005-3129-5109
- 27 Courtney French: 0000-0001-7620-1544
- 28 Cillian Nolan 0009-0006-4092-5499
- 29 William Rowell: 0000-0002-7422-1194
- 30 J. Matthew Holt: 0000-0001-6411-9236
- 31 Christopher T. Saunders: 0000-0002-0726-7600
- 32 Eirini Maria Lampraki 0000-0002-5688-8542
- 33 Margaret Kenna 0000-0003-0851-9272
- 34 Michael Eberle: 0000-0001-8965-1253
- 35 Aiden Eliot Shearer: 0000-0001-8965-1253

It is made available under a CC-BY-NC-ND 4.0 International license .

37 Abstract

38

The diagnostic yield of genetic testing for pediatric sensorineural hearing loss (SNHL) has 39 40 remained at around 40% for over a decade despite newly discovered causative genes and the expanded use of exome sequencing (ES). This stagnation may be due to (1) a 41 focus on coding regions of the genome and (2) an inability to resolve variants in complex 42 genomic regions due to reliance on short-read sequencing technologies. Short-read 43 44 genome sequencing (srGS) and long-read genome sequencing (IrGS) both provide exonic single nucleotide variant (SNV) and small indel detection at the same sensitivity 45 as ES, but also evaluate intronic regions. IrGS provides improved resolution for structural 46 47 variants (SV) and repetitive genomic regions. We sought to investigate the potential utility 48 of IrGS in the diagnostic evaluation of a small cohort of patients with SNHL of unknown etiology after ES and srGS. 19 pediatric patients with SNHL underwent IrGS via PacBio 49 50 SMRT sequencing. Sequencing data were processed using the PacBio WGS variant 51 pipeline. The diagnostic yield for this IrGS cohort was 4/19 (21%). Relevant variants detected only with IrGS included a hemizygous deletion *in trans* with a missense variant 52 53 in an area of high genomic homology (OTOA) and two single nucleotide loss-of-function variants in trans to a known copy-number-loss for a gene with a highly homologous 54 pseudogene (STRC). A complex inversion was identified in the MITF gene which was 55 56 also identified on post-hoc analysis by srGS. LrGS provides improved resolution for 57 complex genomic structural variation which may increase diagnostic yield for genetic 58 pediatric SNHL, and, potentially, rare disease more broadly.

59

60 **Keywords**: long read sequencing, sensorineural hearing loss, hereditary hearing loss

It is made available under a CC-BY-NC-ND 4.0 International license .

61 Introduction

62

Congenital sensorineural hearing loss (SNHL) affects as many as 1 in 500 infants in the 63 64 United States (Morton and Nance 2006) and a majority of these cases are attributable to a Mendelian genetic etiology (Smith et al. 2005). The implementation of comprehensive 65 genetic testing for pediatric SNHL, typically via targeted SNHL gene panels or exome 66 sequencing (ES), results in an overall diagnostic yield of approximately 43% (Downie et 67 68 al. 2020; Perry et al. 2023; Rouse et al. 2022; Shearer 2024; Sloan-Heggen et al. 2016). There is variation in yield based on clinical phenotype and in some populations, for 69 instance congenital severe to profound hearing loss, the diagnostic yield can approach 70 71 60% (Downie et al. 2020; Sloan-Heggen et al. 2016). This diagnostic yield is relatively high compared to other neurodevelopmental disorders for which genetic testing is 72 routinely obtained, such as autism (17%) and epilepsy (24%) (Stefanski et al. 2021). 73 However, this means that up to 60% of children with a high a priori suspicion of a 74 75 hereditary SNHL still go undiagnosed (Kim et al. 2022; Retterer et al. 2016).

76 The most commonly applied testing methodology for the genetic diagnosis of SNHL is targeted gene panels, which rely on short read (150-300bp) sequencing of a targeted list 77 of SNHL genes. Less frequently, pediatric patients with a primary indication of SNHL will 78 undergo ES, also using short-read sequencing technologies. Both gene panels and ES 79 are limited by (1) a focus on exonic or coding regions and nearby splice sites, and (2) low 80 resolution for complex structural variation that contributes to genetic disease. Short-read 81 82 genome sequencing (srGS), which is currently not commonly applied in the clinical 83 evaluation of individuals with SNHL, does provide effective coverage of intronic and 84 noncoding regions (Byrska-Bishop et al. 2022; Pagnamenta et al. 2023).

However, while srGS evaluates noncoding regions of the genome, it is often unable to 85 resolve areas of low complexity, high duplication rate, and structural variation (Chaisson 86 87 et al. 2019; Genomes Project et al. 2015). In fact, much of the human genome maps to 88 segmental duplications, or stretches of DNA over 1kb long with over 90% sequence 89 identity, that are highly mutable but very challenging to resolve using current methodologies (Bailey et al. 2001; Vollger et al. 2023). Two genes that commonly cause 90 nonsyndromic SNHL, OTOA and STRC, map to a segmental duplication and highly 91 homologous pseudogene, respectively, and detecting pathogenic variants within these 92 genes is challenging (Abbasi et al. 2022; Shearer et al. 2014). This is particularly 93 94 important given that pathogenic variation in STRC is the second most common cause of genetic SNHL (Shearer et al 2014). 95

Long-read genome sequencing (IrGS), by contrast, generates sequencing reads up to
several megabases long (Mahmoud et al. 2024; Mantere et al. 2019) and therefore has
high resolution for complex structural variation and repetitive genomic regions. Several
studies over the last few years have shown that long-read techniques have the capacity
to identify Mendelian etiology after standard sequencing techniques have failed, including
a handful of patients with SNHL (Conlin et al. 2022; Miller et al. 2021; Ohori et al. 2021;
Olivucci et al. 2024; Vache et al. 2020; Xie et al. 2020).

103 In this study, our goal was to evaluate the potential utility of IrGS for genetic diagnosis for

pediatric hearing loss in patients with nondiagnostic ES and srGS. We find that IrGS

provided significantly improved resolution for complex structural variation and, in this

106 cohort, substantially improved diagnostic yield over ES and srGS.

107

108 Methods

- 109
- 110 Recruitment and Participants
- 111

112 This research was approved by the Institutional Review Board at Boston Children's Hospital (P00035179 and P00031494) and performed in partnership with the Children's 113 114 Rare Disease Cohort initiative. Pediatric patients with SNHL were recruited in the Boston 115 Children's Hospital Otolaryngology and Communication Enhancement clinical setting and 116 provided written informed consent to participate. Criteria for eligibility included having a clinical diagnosis of SNHL that did not have a known genetic etiology; there were no 117 118 exclusions based on other clinical criteria, including age of onset, laterality or severity of 119 hearing loss, presence of syndromic features, or family history. All patients had diagnostic 120 work up for sensorineural hearing loss including audiometric testing and clinical evaluation; many had additional diagnostic workup including congenital cytomegalovirus 121 122 (cCMV) testing and temporal bone imaging (CT and/or MRI).

- 123
- 124 Genetic Testing Methodologies

125

Prior to IrGS through this study, genetic testing methodologies varied based on individual patient circumstances. Some probands had prior single gene sequencing or targeted hearing loss gene panel sequencing on a clinical basis. All probands had research exome sequencing, and most probands had srGS performed on a research basis prior to research IrGS. Prior genetic testing, regardless of methodology, was deemed nondiagnostic by the testing laboratory and clinical team.

- 132
- 133 DNA Extraction, Sequencing, and Analysis
- 134

135 DNA was extracted from whole blood using standard methods. 150bp paired end ES and 136 srGS was performed at GeneDx using Illumina sequencers. ES and srGS data were 137 processed using Illumina Dragen v3.9 as previously described (Rockowitz et al. 2020). 138 For PacBio sequencing, 12-15 kb insert SMRTbell libraries were prepared using the 139 SMRTbell prep kit 3.0. Long-read whole genome sequencing was performed using Single 140 Molecule, Real-Time (SMRT) sequencing at Pacific Biosciences ("PacBio,") (Menlo Park, 141 CA) using the PacBio Sequel II system to a depth of 24-32x coverage. Sequence data was processed by PacBio variant pipeline. Unaligned HiFi reads in BAM format were 142 received from PacBio. Read alignment and variant calling were performed using PacBio 143 144 HiFi-human-WGS-WDL workflow v1.0.3. In short, HiFi reads were aligned to the GRCh38 (GCA 000001405.15) genome using pbmm2 v1.10.0. Single nucleotide variants, small 145 146 insertions and deletions were identified with DeepVariant v1.5.0 (Poplin et al. 2018). Structural variants were called with pbsv v2.9.0. Copy number variations were called with 147 148 HiFiCNV v0.1.7. Short tandem repeat expansion was identified using TRGT v0.5.0. Small

It is made available under a CC-BY-NC-ND 4.0 International license .

variants and structural variants were jointly phased with HiPhase v0.10.2 (Holt et al.
2024), and phase haplotype tags ("HP") were added to the aligned BAM file. Variant
calling results were further processed using in house bioinformatic pipelines and analyzed
via GeneDx Discovery Platform. For each candidate variant, sequencing reads were
visually reviewed using IGV v2.16.0.

154

155 *Clinical Confirmation and Return of Results*

156

157 Variant pathogenicity was determined according to the American College of Medical 158 Genetics and the Associations for Molecular Pathology guidelines as modified for SNHL-159 specific considerations (Oza et al. 2018; Richards et al. 2015). Candidate variants that 160 were identified via research analysis of IrGS were clinically confirmed using an additional clinical sample and orthogonal genetic testing method within a commercial genetic testing 161 laboratory (Prevention Genetics, Marshfield, WI) environment with Clinical Laboratory 162 163 Improvement Amendments (CLIA) approval. Clinically confirmed variant results were returned to families and genetic counseling was provided by a certified and licensed 164 165 genetic counselor and otolaryngologist.

166

167 168 **Results**

169

170 Subject Demographic and Clinical Characteristics

- 171 172 Nineteen probands underwent IrGS through this study (Table 1). The median age at the time of results was 7-years-old (with an interguartile range of 5.1-years-old to 9.7-years-173 174 old). Fifteen (79%) probands had a bilateral symmetric SNHL, three (15.8%) had bilateral 175 asymmetric hearing loss, and one (5.2%) had unilateral SNHL with bilateral enlarged 176 vestibular aqueducts. Twelve probands (63%) had congenital onset SNHL, 2 (10.5%) had 177 prelingual SNHL, 3 (15.8%) had postlingual SNHL, and onset of SNHL was unknown for 178 2 probands (10.5%). Severity of SNHL was highly variable (Supplemental Table 1). Two (10.5%) probands had an autosomal recessive family history of SNHL, two (10.5%) had 179 an autosomal dominant family history of SNHL, and 15 (78.9%) had no reported family 180 181 history. Five (33.3%) probands had notable extra-auditory clinical presentations including 182 hemolytic anemia; retinal dystrophy; global developmental delay; hypotonia, low vision, 183 and nystagmus, and hematuria in one proband each.
- 184

185 All probands had extensive genetic testing prior to IrGS, the primary indication for which was SNHL. Three probands (15.8%) had single gene (GJB2) testing, four probands (21%) 186 187 had SNHL gene panel testing, 19 probands (100%) had exome sequencing, and 18 188 probands (94.7%) had short read genome sequencing. Testing was nondiagnostic for all 189 19 probands on initial analysis. Nine probands (47.4%) were identified to harbor a 190 heterozygous pathogenic or likely pathogenic variant in a gene that was associated 191 exclusively or primarily with autosomal recessive conditions, including two probands with 192 a heterozygous loss of STRC (full patient details are included in **Supp. Table 1**).

- 193
- 194 Long Read Genome Sequencing:

It is made available under a CC-BY-NC-ND 4.0 International license .

195

The median read length across 19 samples was 13.5 kb (1.2 kb standard deviation). The median depth of coverage of IrGS across samples was 29.5x (3.5x standard deviation). On average, per sample, 5,386,525 single nucleotide variants were detected (range 5,305,533-5,533,276) and 22,004 structural variants were detected (range 19,838-23,049). The number of variants, both SNVs and SVs, detected through ES and srGS of these same patients was significantly lower than for IrGS (**Table 2 and Supp. Table 2**).

202

LrGS and analysis was completed for 19 probands. Genetic variants were identified for 4 of the 19 probands that were assessed to be causative or potentially causative resulting in a diagnostic yield of 21.1%.

206

207 Case Vignettes

208 209 **Case 1**:

210 Proband 1 is a with a bilateral mild-moderate SNHL who is otherwise healthy. Proband 211 referred bilaterally on the newborn hearing screen in the neonatal period. Two diagnostic auditory brainstem response (ABR) tests in infancy showed a bilateral SNHL in the mild 212 range of severity. Subsequent behavioral audiometric evaluations in childhood have been 213 214 consistent with a stable bilateral mild sensorineural hearing loss. The proband has an 215 older sibling with a similar history and audiological profile. There is otherwise no family history of SNHL. Proband had cytomegalovirus (CMV) testing in the newborn period that 216 217 was negative. She has not had diagnostic imaging of the inner ear. Research ES for proband, sibling, and parents was nondiagnostic but did identify a heterozygous copy 218 number loss at chromosome 15g15.3 encompassing the STRC and CATSPER2 genes. 219 220 No second variant was detected. SrGS did not identify any further notable variants.

221

IrGS identified a pathogenic nonsense mutation in trans with a hemizygous deletion of 222 223 STRC and CATSPER2 (Figure 1A). The depth-based CNV caller HiFiCNV detected a 224 104 kb deletion (approx. chr15:43.566.001-43.670.000). On the other allele. DeepVariant (Poplin et al. 2018) analysis identified the variant NM 153700.2:c.1228C>A, p.(GIn410*) 225 226 (chr15:43,616,338 G>A). This variant is absent from gnomAD, ClinVar, and LOVD and 227 results in a stop gain in an exon that is challenging to map with short reads due to a highly similar paralog. Interestingly, phasing analysis using Paraphase (Chen et al. 2023) 228 229 enabled visualization of a single STRC haplotype and two pseudogene haplotypes of 230 pSTRC (Figure 1A). This phasing analysis of a complex region helps to confirm segregation. Both STRC variants were clinically confirmed and disclosed to the family. 231 LrGS was able to help resolve this SNV when other methods could not, due to the highly 232 233 homologous pseudogene pSTRC.

234

235 Case 2:

Proband 2 is a male with a bilateral mild to moderate SNHL who is otherwise healthy. He
did not pass a newborn hearing screen. An ABR performed in infancy identified a mild

238 SNHL. A recent behavioral audiometric evaluation in childhood showed a bilateral mild to

moderate SNHL. The proband had negative CMV testing in the newborn period. He has

240 not had diagnostic imaging of the inner ear. Research trio ES identified a heterozygous

CNV at 15q15.3 encompassing the *STRC* and *CATSPER2* genes. SrGS was nondiagnostic. Similar to Case 1, LrGS identified a single nucleotide variant in *STRC* (NM_153700.2:c.3217C>T, p.(Arg1073*)) *in trans* to the CNV which was classified as pathogenic. Following the identification of these *STRC* variants, another sibling to proband 2 was born and identified to have a mild bilateral SNHL shortly after birth; results of targeted STRC variant testing for this sibling are pending.

- 247
- 248
- 249 Case 3:

Proband 3 is a female with a bilateral SNHL. She did not pass a newborn hearing screen 250 251 bilaterally. Initial ABR in infancy identified a bilateral SNHL that was moderate in severity. 252 A recent hearing test in childhood demonstrated a slightly u-shaped audiogram 253 configuration in the moderate to moderately-severe range of severity. She had CMV testing that was negative. She has not had diagnostic imaging of the inner ear. Targeted 254 255 gene panel testing identified a heterozygous likely pathogenic variant in MYO7A (Supp. Table 1.) The proband's unaffected parent also harbored this variant. Research exome 256 257 and srGS were nondiagnostic with no further variants of interest identified.

258

259 LrGS identified a copy number variant (CNV) (loss of 769bp at chr16:21,735,945) 260 including exon 22 of OTOA in trans with a heterozygous missense variant (NM 144672.3:c.2654A>G, p.(His885Arq)) in the OTOA gene (Figure 1B). This result 261 262 was deemed to be possibly/likely diagnostic of OTOA-associated nonsyndromic hearing loss. However, the missense variant in OTOA is currently classified as a variant of 263 264 uncertain significance. OTOA is within a segmental duplication. Neither variant in OTOA had been appreciated before IrGS; upon review, the srGS analysis pipeline had called the 265 266 His885Arg missense variant, but it had been filtered out of the list of candidate variants due to low call quality (poor coverage and mapping quality). The CNV was detected only 267 268 by IrGS.

269 270 **Case 4**:

Proband 4 is a female with a bilateral asymmetric SNHL. She passed a newborn hearing screen bilaterally. Failing a hearing screen in early childhood prompted audiological assessment. Behavioral audiometry identified a mild low-frequency SNHL, which has progressed slightly since first identified. In the right ear, hearing is in the moderate rising to normal range of severity. In the left ear, hearing has been in the slight sloping to moderate rising to normal range of severity. *GJB2* sequencing was negative. Research ES was nondiagnostic.

278

IrGS identified a 403.2kb inversion (chr3:69977069_70380310inv) upstream of the *MITF*gene predicted to impact alternatively spliced transcripts of *MITF*. Similar inversions have
not been reported before, so this variant was classified as a variant of uncertain
significance though it is suspected to be causative of the proband's SNHL. This copyneutral inversion was subsequently identified on srGS upon reanalysis of data using an
updated tertiary analysis pipeline.

- 285
- 286 **Discussion**

It is made available under a CC-BY-NC-ND 4.0 International license .

287

288 Despite increasing access to comprehensive genetic testing for pediatric SNHL patients, 289 the discovery of additional SNHL genes, and decreasing costs of testing, the diagnostic 290 yield of the genetic evaluation of SNHL remains at approximately 43% over the past 291 decade (Shearer 2024). While this diagnostic rate is high compared to other indications 292 for genomic testing in children (Malinowski et al. 2020; Manickam et al. 2021; Vandersluis 293 et al. 2020), there remains a gap between the actual diagnostic rate and the suspected 294 true prevalence of hereditary hearing loss (Smith et al. 2005). Furthermore, the improvement in the diagnostic yield for hearing loss as well as other pediatric rare 295 diseases seems only modestly increased when comparing srGS to ES (Wojcik et al. 296 297 2024). Identifying the underlying cause of SNHL in pediatric patients is critical to providing 298 tailored, high-quality care. Determining the genetic etiology of SNHL facilitates accurate genetic counseling and recurrence counseling, provides valuable information on 299 prognosis that may impact treatment decisions, and allows for the identification and 300 301 appropriate follow-up for children with syndromic SNHL. Ongoing clinical trials for targeted gene therapies for DFNB9 further emphasize the utility of precision medicine in 302 303 the care of pediatric SNHL patients and the potential impact of an accurate genetic 304 diagnosis (Lv et al. 2024).

305

306 Given the relatively high prevalence of pediatric SNHL in the population, an increase in 307 the overall genetic diagnostic rate is poised to result in many more diagnoses per year, in 308 absolute terms. The STRC gene alone has a carrier frequency of approximately 1.5% in 309 the general population, and accounts for around 15% of all cases hereditary hearing loss (Han et al. 2021; Perry et al. 2023; Shearer et al. 2014; Shubina-Oleinik et al. 2021; Sloan-310 311 Heggen et al. 2016). However, due to the STRC pseudogene and complexity of this 312 genomic region, many commercial labs will only perform CNV analysis without 313 sequencing or omit STRC from gene panels altogether. We posit that STRC is, therefore, meaningfully under-diagnosed. We performed IrGS for two unrelated probands with 314 315 congenital mild-moderate SNHL and a heterozygous loss of STRC, resulting in a high a 316 priori suspicion for a missing second STRC variant. IrGS confirmed that suspicion. 317 resolving loss-of-function SNVs in trans to a CNV for both probands. While less prevalent 318 than STRC-, OTOA-mediated hearing loss is likely underdiagnosed as well due to its 319 locus in a segmental duplication. Indeed, an estimated 7% of the human genome consists 320 of segmental duplications that are highly mutable (Vollger et al. 2023; Vollger et al. 2022). 321

This work underscores the promise of IrGS to improve detection of variants in complex 322 323 and difficult-to-resolve genomic regions and increase diagnostic yield. In this study, we 324 selected a cohort of 19 probands with pediatric SNHL who had already had extensive 325 genetic evaluation. We were able to identify four additional diagnoses and confirm a complex structural variant, leading to a diagnostic rate of 21.1% using IrGS. Emerging 326 327 studies comparing the genetic diagnosis of rare disease using ES and srGS do not report 328 a significant improvement in the yield of srGS over ES (Chung et al. 2023). SrGS remains 329 more expensive than ES and more time-consuming to analyze. It is, in fact, not a part of 330 routine clinical care to order srGS across most clinical indications, including pediatric 331 SNHL. Sample sizes are small, but published rare disease studies using IrGS, including

this one, hint at the potential for improved yield over other methodologies (Mahmoud et al. 2024; Miller et al. 2021; Pagnamenta et al. 2023; Xie et al. 2020).

334

335 LrGS, while not currently available on a clinical basis, offers a single test to identify SNV. CNVS, small insertion and deletions, tandem repeats, SVs, and methylation changes 336 337 across both simple and complex genomic regions. In addition, this technology provides 338 phasing information which may be advantageous for discrimination of pathogenic 339 variation. For the patients in this small cohort, each had undergone extensive genetic 340 testing prior to IrGS. While IrGS remains costly compared to other testing modalities, 341 eliminating the use of other high-cost, low-yield tests such as srGS may ultimately be 342 more beneficial to all stakeholders.

343

Limitations of our study include the small cohort size as well as the selection of probands for inclusion based on high *a priori* suspicion of a mendelian condition based on clinical characteristics. Future work should include a larger sample size of less highly selected patients with pediatric SNHL.

348

349 Conclusions

350

Long read sequencing, while not in use clinically, has shown promise as a single test capable of detecting diverse genomic variant types in both simple and complex genomic regions. We describe four diagnoses identified in a cohort of 19 pediatric patients with SNHL who had undergone extensive nondiagnostic testing prior to IrGS, further highlighting the promise of this technology to significantly increase diagnostic rates.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 356 Bibliography
- Abbasi W, French CE, Rockowitz S, Kenna MA, Eliot Shearer A (2022) Evaluation of copy
 number variants for genetic hearing loss: a review of current approaches and
 recent findings. Hum Genet 141: 387-400. https://doi.org/10.1007/s00439-02102365-1
- Bailey JA, Yavor AM, Massa HF, Trask BJ, Eichler EE (2001) Segmental duplications:
 organization and impact within the current human genome project assembly.
 Genome Res 11: 1005-17. https://doi.org/10.1101/gr.gr-1871r
- Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, Corvelo A, Clarke
 WE, Musunuri R, Nagulapalli K, Fairley S, Runnels A, Winterkorn L, Lowy E,
 Human Genome Structural Variation C, Paul F, Germer S, Brand H, Hall IM,
 Talkowski ME, Narzisi G, Zody MC (2022) High-coverage whole-genome
 sequencing of the expanded 1000 Genomes Project cohort including 602 trios.
 Cell 185: 3426-3440 e19. https://doi.org/10.1016/j.cell.2022.08.004
- 371 Chaisson MJP, Sanders AD, Zhao X, Malhotra A, Porubsky D, Rausch T, Gardner EJ, 372 Rodriguez OL, Guo L, Collins RL, Fan X, Wen J, Handsaker RE, Fairley S, Kronenberg ZN, Kong X, Hormozdiari F, Lee D, Wenger AM, Hastie AR, Antaki D, 373 374 Anantharaman T, Audano PA, Brand H, Cantsilieris S, Cao H, Cerveira E, Chen C, 375 Chen X, Chin CS, Chong Z, Chuang NT, Lambert CC, Church DM, Clarke L, Farrell A, Flores J, Galeev T, Gorkin DU, Gujral M, Guryev V, Heaton WH, Korlach J, 376 377 Kumar S, Kwon JY, Lam ET, Lee JE, Lee J, Lee WP, Lee SP, Li S, Marks P, Viaud-378 Martinez K, Meiers S, Munson KM, Navarro FCP, Nelson BJ, Nodzak C, Noor A, Kyriazopoulou-Panagiotopoulou S, Pang AWC, Qiu Y, Rosanio G, Ryan M, Stutz 379 A, Spierings DCJ, Ward A, Welch AE, Xiao M, Xu W, Zhang C, Zhu Q, Zheng-380 381 Bradley X, Lowy E, Yakneen S, McCarroll S, Jun G, Ding L, Koh CL, Ren B, Flicek P, Chen K, Gerstein MB, Kwok PY, Lansdorp PM, Marth GT, Sebat J, Shi X, Bashir 382 383 A. Ye K. Devine SE. Talkowski ME. Mills RE. Marschall T. Korbel JO. Eichler EE. 384 Lee C (2019) Multi-platform discovery of haplotype-resolved structural variation in 385 human genomes. Nat Commun 10: 1784. https://doi.org/10.1038/s41467-018-386 08148-z
- 387 Chen X, Harting J, Farrow E, Thiffault I, Kasperaviciute D, Genomics England Research 388 C, Hoischen A, Gilissen C, Pastinen T, Eberle MA (2023) Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio 389 390 HiFi seauencina. Am J Hum Genet 110: 240-250. https://doi.org/10.1016/j.ajhg.2023.01.001 391
- Chung CCY, Hue SPY, Ng NYT, Doong PHL, Hong Kong Genome P, Chu ATW, Chung BHY (2023) Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations. Genet Med 25: 100896. https://doi.org/10.1016/j.gim.2023.100896
- Conlin LK, Aref-Eshghi E, McEldrew DA, Luo M, Rajagopalan R (2022) Long-read
 sequencing for molecular diagnostics in constitutional genetic disorders. Hum
 Mutat 43: 1531-1544. https://doi.org/10.1002/humu.24465
- Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, Poulakis Z, Gaff C, Sung V,
 Wake M, Hunter MF, Saunders K, Rose E, Lewis S, Jarmolowicz A, Phelan D,

402	Rehm HL, Melbourne Genomics Health A, Amor DJ (2020) Exome sequencing in
403	infants with congenital hearing impairment: a population-based cohort study. Eur
404	J Hum Genet 28: 587-596. https://doi.org/10.1038/s41431-019-0553-8
405	Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO,
406	Marchini JL, McCarthy S, McVean GA, Abecasis GR (2015) A global reference for
407	human genetic variation. Nature 526: 68-74. https://doi.org/10.1038/nature15393
408	Han S, Zhang D, Guo Y, Fu Z, Guan G (2021) Prevalence and Characteristics of STRC
409	Gene Mutations (DFNB16): A Systematic Review and Meta-Analysis. Front Genet
410	12: 707845. https://doi.org/10.3389/fgene.2021.707845
411	Holt JM, Saunders CT, Rowell WJ, Kronenberg Z, Wenger AM, Eberle M (2024) HiPhase:
412	jointly phasing small, structural, and tandem repeat variants from HiFi sequencing.
413	Bioinformatics 40. https://doi.org/10.1093/bioinformatics/btae042
414	Kim YS, Kim Y, Jeon HW, Yi N, Lee SY, Kim Y, Han JH, Kim MY, Kim BH, Choi HY,
415	Carandang M, Koo JW, Kim BJ, Bae YJ, Choi BY (2022) Full etiologic spectrum of
416	pediatric severe to profound hearing loss of consecutive 119 cases. Sci Rep 12:
417	12335. https://doi.org/10.1038/s41598-022-16421-x
418	Lv J, Wang H, Cheng X, Chen Y, Wang D, Zhang L, Cao Q, Tang H, Hu S, Gao K, Xun
419	M, Wang J, Wang Z, Zhu B, Cui C, Gao Z, Guo L, Yu S, Jiang L, Yin Y, Zhang J,
420	Chen B, Wang W, Chai R, Chen ZY, Li H, Shu Y (2024) AAV1-hOTOF gene therapy
421	for autosomal recessive deafness 9: a single-arm trial. Lancet 403: 2317-2325.
422	https://doi.org/10.1016/S0140-6736(23)02874-X
423	Mahmoud M, Huang Y, Garimella K, Audano PA, Wan W, Prasad N, Handsaker RE, Hall
424	S, Pionzio A, Schatz MC, Talkowski ME, Eichler EE, Levy SE, Sedlazeck FJ (2024)
425	Utility of long-read sequencing for All of Us. Nat Commun 15: 837.
426	https://doi.org/10.1038/s41467-024-44804-3
427	Malinowski J, Miller DT, Demmer L, Gannon J, Pereira EM, Schroeder MC, Scheuner MT,
428	Tsai AC, Hickey SE, Shen J, Practice AP, Guidelines C (2020) Systematic
429	evidence-based review: outcomes from exome and genome sequencing for
430	pediatric patients with congenital anomalies or intellectual disability. Genet Med
431	22: 986-1004. <u>https://doi.org/</u> 10.1038/s41436-020-0771-z
432	Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J,
433	Massingham LJ, Miller D, Yu TW, Hisama FM, Directors ABo (2021) Exome and
434	genome sequencing for pediatric patients with congenital anomalies or intellectual
435	disability: an evidence-based clinical guideline of the American College of Medical
436	Genetics and Genomics (ACMG). Genet Med 23: 2029-2037.
437	https://doi.org/10.1038/s41436-021-01242-6
438	Mantere T, Kersten S, Hoischen A (2019) Long-Read Sequencing Emerging in Medical
439	Genetics. Front Genet 10: 426. https://doi.org/10.3389/fgene.2019.00426
440	Miller DE, Sulovari A, Wang T, Loucks H, Hoekzema K, Munson KM, Lewis AP, Fuerte
441	EPA, Paschal CR, Walsh T, Thies J, Bennett JT, Glass I, Dipple KM, Patterson K,
442	Bonkowski ES, Nelson Z, Squire A, Sikes M, Beckman E, Bennett RL, Earl D, Lee
443	W, Allikmets R, Perlman SJ, Chow P, Hing AV, Wenger TL, Adam MP, Sun A, Lam
444	C, Chang I, Zou X, Austin SL, Huggins E, Safi A, Iyengar AK, Reddy TE, Majoros
445	WH, Allen AS, Crawford GE, Kishnani PS, University of Washington Center for
446	Mendelian G, King MC, Cherry T, Chong JX, Bamshad MJ, Nickerson DA, Mefford
447	HC, Doherty D, Eichler EE (2021) Targeted long-read sequencing identifies

448 missing disease-causing variation. Am J Hum Genet 108: 1436-1449. 449 https://doi.org/10.1016/j.ajhg.2021.06.006

- 450 Morton CC, Nance WE (2006) Newborn hearing screening--a silent revolution. N Engl J 451 Med 354: 2151-64. https://doi.org/10.1056/NEJMra050700
- Ohori S, Tsuburaya RS, Kinoshita M, Miyagi E, Mizuguchi T, Mitsuhashi S, Frith MC,
 Matsumoto N (2021) Long-read whole-genome sequencing identified a partial
 MBD5 deletion in an exome-negative patient with neurodevelopmental disorder. J
 Hum Genet 66: 697-705. https://doi.org/10.1038/s10038-020-00893-8
- Olivucci G, Iovino E, Innella G, Turchetti D, Pippucci T, Magini P (2024) Long read
 sequencing on its way to the routine diagnostics of genetic diseases. Front Genet
 15: 1374860. https://doi.org/10.3389/fgene.2024.1374860
- Oza AM, DiStefano MT, Hemphill ŠE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin
 A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT,
 Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN,
 ClinGen Hearing Loss Clinical Domain Working G (2018) Expert specification of
 the ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum
 Mutat 39: 1593-1613. https://doi.org/10.1002/humu.23630
- 465 Pagnamenta AT, Camps C, Giacopuzzi E, Taylor JM, Hashim M, Calpena E, Kaisaki PJ, 466 Hashimoto A, Yu J, Sanders E, Schwessinger R, Hughes JR, Lunter G, Dreau H, 467 Ferla M, Lange L, Kesim Y, Ragoussis V, Vavoulis DV, Allroggen H, Ansorge O, Babbs C, Banka S, Banos-Pinero B, Beeson D, Ben-Ami T, Bennett DL, Bento C, 468 469 Blair E, Brasch-Andersen C, Bull KR, Cario H, Cilliers D, Conti V, Davies EG, 470 Dhalla F, Dacal BD, Dong Y, Dunford JE, Guerrini R, Harris AL, Hartley J, Hollander 471 G, Javaid K, Kane M, Kelly D, Kelly D, Knight SJL, Kreins AY, Kvikstad EM, Langman CB, Lester T, Lines KE, Lord SR, Lu X, Mansour S, Manzur A, Maroofian 472 473 R, Marsden B, Mason J, McGowan SJ, Mei D, Mlcochova H, Murakami Y, Nemeth AH, Okoli S, Ormondroyd E, Ousager LB, Palace J, Patel SY, Pentony MM, Pugh 474 475 C. Rad A. Ramesh A. Riva SG. Roberts I. Rov N. Salminen O. Schilling KD. Scott 476 C, Sen A, Smith C, Stevenson M, Thakker RV, Twigg SRF, Uhlig HH, van Wijk R, 477 Vona B. Wall S. Wang J. Watkins H. Zak J. Schuh AH, Kini U. Wilkie AOM, Popitsch 478 N, Taylor JC (2023) Structural and non-coding variants increase the diagnostic 479 vield of clinical whole genome sequencing for rare diseases. Genome Med 15: 94. 480 https://doi.org/10.1186/s13073-023-01240-0
- Perry J, Redfield S, Oza A, Rouse S, Stewart C, Khela H, Srinivasan T, Albano V, Shearer
 E, Kenna M (2023) Exome Sequencing Expands the Genetic Diagnostic Spectrum
 for Pediatric Hearing Loss. Laryngoscope 133: 2417-2424.
 https://doi.org/10.1002/lary.30507
- Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, Newburger D, Dijamco
 J, Nguyen N, Afshar PT, Gross SS, Dorfman L, McLean CY, DePristo MA (2018) A
 universal SNP and small-indel variant caller using deep neural networks. Nat
 Biotechnol 36: 983-987. https://doi.org/10.1038/nbt.4235
- Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N,
 Neidich J, Monaghan KG, McKnight D, Bai R, Suchy S, Friedman B, Tahiliani J,
 Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK, Bale S (2016)
 Clinical application of whole-exome sequencing across clinical indications. Genet
 Med 18: 696-704. https://doi.org/10.1038/gim.2015.148

- 494 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon 495 E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and 496 guidelines for the interpretation of sequence variants: a joint consensus 497 recommendation of the American College of Medical Genetics and Genomics and 498 Association for Molecular Pathology. Genet Med the 17: 405-24. 499 https://doi.org/10.1038/gim.2015.30
- Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, Knight D, Sexton
 E, Smith L, Sheidley B, Field M, Holm IA, Brownstein CA, Agrawal PB, Kornetsky
 S, Poduri A, Snapper SB, Beggs AH, Yu TW, Williams DA, Sliz P (2020) Children's
 rare disease cohorts: an integrative research and clinical genomics initiative. NPJ
 Genom Med 5: 29. https://doi.org/10.1038/s41525-020-0137-0
- Rouse SL, Florentine MM, Taketa E, Chan DK (2022) Racial and ethnic disparities in
 genetic testing for hearing loss: a systematic review and synthesis. Hum Genet
 141: 485-494. <u>https://doi.org/</u>10.1007/s00439-021-02335-7
- Shearer AE, Kolbe DL, Azaiez H, Sloan CM, Frees KL, Weaver AE, Clark ET, Nishimura 511 512 CJ, Black-Ziegelbein EA, Smith RJ (2014) Copy number variants are a common 513 cause of non-syndromic hearing loss. Genome Med 6: 37. https://doi.org/10.1186/gm554 514
- Shubina-Oleinik O, Nist-Lund C, French C, Rockowitz S, Shearer AE, Holt JR (2021)
 Dual-vector gene therapy restores cochlear amplification and auditory sensitivity
 in a mouse model of DFNB16 hearing loss. Sci Adv 7: eabi7629.
 https://doi.org/10.1126/sciadv.abi7629
- Sloan-Heggen CM, Bierer AO, Shearer AE, Kolbe DL, Nishimura CJ, Frees KL, Ephraim
 SS, Shibata SB, Booth KT, Campbell CA, Ranum PT, Weaver AE, Black-Ziegelbein
 EA, Wang D, Azaiez H, Smith RJH (2016) Comprehensive genetic testing in the
 clinical evaluation of 1119 patients with hearing loss. Hum Genet 135: 441-450.
 https://doi.org/10.1007/s00439-016-1648-8
- 524 Smith RJ, Bale JF, Jr., White KR (2005) Sensorineural hearing loss in children. Lancet 365: 879-90. https://doi.org/ 10.1016/S0140-6736(05)71047-3
- Stefanski A, Calle-Lopez Y, Leu C, Perez-Palma E, Pestana-Knight E, Lal D (2021)
 Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual
 disability: A systematic review and meta-analysis. Epilepsia 62: 143-151.
 https://doi.org/10.1111/epi.16755
- Vache C, Puechberty J, Faugere V, Darmaisin F, Liquori A, Baux D, Blanchet C, GarciaGarcia G, Meunier I, Pellestor F, Koenig M, Roux AF (2020) A 4.6 Mb Inversion
 Leading to PCDH15-LINC00844 and BICC1-PCDH15 Fusion Transcripts as a
 New Pathogenic Mechanism Implicated in Usher Syndrome Type 1. Front Genet
 11: 623. https://doi.org/10.3389/fgene.2020.00623
- Vandersluis S, M.L. C, L. C, O. G-V, D. W, C. H (2020) Genome-Wide Sequencing for
 Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A
 Health Technology Assessment. Ont Health Technol Assess Ser 20: 1-178.
- 538 Vollger MR, Dishuck PC, Harvey WT, DeWitt WS, Guitart X, Goldberg ME, Rozanski AN, 539 Lucas J, Asri M, Human Pangenome Reference C, Munson KM, Lewis AP,

It is made available under a CC-BY-NC-ND 4.0 International license .

540Hoekzema K, Logsdon GA, Porubsky D, Paten B, Harris K, Hsieh P, Eichler EE541(2023) Increased mutation and gene conversion within human segmental542duplications. Nature 617: 325-334. https://doi.org/10.1038/s41586-023-05895-y

- Vollger MR, Guitart X, Dishuck PC, Mercuri L, Harvey WT, Gershman A, Diekhans M,
 Sulovari A, Munson KM, Lewis AP, Hoekzema K, Porubsky D, Li R, Nurk S, Koren
 S, Miga KH, Phillippy AM, Timp W, Ventura M, Eichler EE (2022) Segmental
 duplications and their variation in a complete human genome. Science 376:
 eabj6965. https://doi.org/10.1126/science.abj6965
- Wojcik MH, Lemire G, Berger E, Zaki MS, Wissmann M, Win W, White SM, Weisburd B, 548 549 Wieczorek D, Waddell LB, Verboon JM, VanNoy GE, Topf A, Tan TY, Syrbe S, Strehlow V, Straub V, Stenton SL, Snow H, Singer-Berk M, Silver J, Shril S, Seaby 550 EG, Schneider R, Sankaran VG, Sanchis-Juan A, Russell KA, Reinson K, 551 Ravenscroft G, Radtke M, Popp D, Polster T, Platzer K, Pierce EA, Place EM, 552 553 Pajusalu S, Pais L, Ounap K, Osei-Owusu I, Opperman H, Okur V, Oja KT, O'Leary M, O'Heir E, Morel CF, Merkenschlager A, Marchant RG, Mangilog BE, Madden 554 JA, MacArthur D, Lovgren A, Lerner-Ellis JP, Lin J, Laing N, Hildebrandt F, 555 556 Hentschel J. Groopman E. Goodrich J. Gleeson JG. Ghaoui R. Genetti CA. 557 Gburek-Augustat J, Gazda HT, Ganesh VS, Ganapathi M, Gallacher L, Fu JM, Evangelista E, England E, Donkervoort S, DiTroia S, Cooper ST, Chung WK, 558 559 Christodoulou J, Chao KR, Cato LD, Bujakowska KM, Bryen SJ, Brand H, Bonnemann CG, Beggs AH, Baxter SM, Bartolomaeus T, Agrawal PB, Talkowski 560 M, Austin-Tse C, Abou Jamra R, Rehm HL, O'Donnell-Luria A (2024) Genome 561 Sequencing for Diagnosing Rare Diseases. N Engl J Med 390: 1985-1997. 562 https://doi.org/10.1056/NEJMoa2314761 563
- Xie Z, Sun C, Zhang S, Liu Y, Yu M, Zheng Y, Meng L, Acharya A, Cornejo-Sanchez DM,
 Wang G, Zhang W, Schrauwen I, Leal SM, Wang Z, Yuan Y (2020) Long-read
 whole-genome sequencing for the genetic diagnosis of dystrophinopathies. Ann
 Clin Transl Neurol 7: 2041-2046. https://doi.org/10.1002/acn3.51201
- 568

It is made available under a CC-BY-NC-ND 4.0 International license .

Figures 571

Figure 1 Causative variants identified via long-read genome sequencing (IrGS). A) Top panel shows identification of compound heterozygous pathogenic variant and hemizygous deletion in *STRC*. Bottom panel shows haplotype analysis indicating two *STRCP1* haplotypes and only one *STRC* haplotype, with roughly half of the expected coverage (CN1), containing a G>A stop gain at chr15:43,616,338. B) Identification of a single exon deletion (exon 22) and stop mutation in compound heterozygosity in the *OTOA* gene. C) Identification of a copy-neutral inversion in the *MITF* gene.



It is made available under a CC-BY-NC-ND 4.0 International license .

580 Tables

Table 1: Cohort demographic and clinical characteristics. IrGS: long-read genome 583 sequencing.

Characteristic	lrGS Cohort n (%			
Total	19 (100%)			
Sex				
Female	13 (68.4%)			
Male	6 (31.6%)			
Race				
White	16 (82.4%)			
Not Reported	1 (5.2%)			
Asian	1 (5.2%)			
Hispanic/Latino	1 (5.2%)			
Positive Family History (of childhood-onset				
No	15 (78.9%)			
Yes	4 (21.1%)			
HL Onset				
Congenital	12 (63.1%)			
Prelingual	2 (10.5%)			
Postlingual	3 (15.8%)			
Unknown	2 (10.5%)			
HL Laterality				
Bilateral, symmetric	15 (78.9%)			
Unilateral	1 (5.2%)			
Bilateral, asymmetric	3 (15.8%)			
HL Severity (in worse ear)				
Mild-Moderate	9 (47.4%)			
Severe-Profound	10 (52.6%)			
Syndromic Features				
Yes	5 (26.3%)			
No	14 (73.7%)			
Previous Genetic Testing				
Single gene	3 (15.8%)			
Gene panel	4 (21.1%)			
Exome sequencing	19 (100%)			
Short read genome sequencing	18 (94.7%)			

Table 2. Key sequencing statistics using exome sequencing (ES), short-read genome sequencing (srGS) and long-read genome sequencing (IrGS).

Method	ES	srGS	PacBio IrGS
N Samples	19	18	19
Read Length (bp)	150	150	13,539
Avg Depth of Coverage	75.5	50.9	29.5
SNV Detected (T-test* significance			
relative to IrGS)	117,336** (p=4.2E-36)	5,039,980 (p=1.2E-18)	5,386,525
SV Detected (T-test* significance			
relative to IrGS)	78 [†] (p=1.5E-28)	12,273 (p=6.6E-15)	22,004

590 SNV = single nucleotide variant, SV = structural variant. *Two-tailed paired T-test. **T-test significance ES relative to srGS

for SNVs: 5.1E-34. [†]T-test significance ES relative to srGS for SVs: 9.6E-17.

593 Statements and Declarations

- 594 Acknowledgments
- 595 We thank the families for their participation.

596 Funding

597 This work was funded by NIDCD K08 DC19716 and by Escuchar Sin Fronteras Foundation to AES with support from the 598 Boston Children's Hospital Rare Disease Cohort Initiative.

- 599
- 600 Author contributions

AES and SER conceived the study. CTS and JMH contributed software. AES, CEF, CN, SER, WJR, and WS performed formal analyses that were validated by AES, CEF, SER, and WS. MZ, AP, CF, CL, EML, SER, and TS conducted the investigation process. AES, MK, and SER secured patient resources. AES, CEF, SER, and WS performed data curation. AES and SER wrote the original draft. AES, CEF, CN, EML, MK, SR, SER, WJR, and WS contributed to reviewing and editing. AES and SER prepared figures. AES, ME, MK, and SR provided supervision. SER, SR, and CEF contributed to project administration. All authors reviewed and approved of the manuscript.

- 607 Data Availability
- 608 Most data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional 609 data related to this paper may be requested from the authors.
- 610 Compliance with ethical standards
- 611 Conflict of interest

AES is the principal investigator of an investigator initiated clinical trial, Genetic Newborn Hearing Screening, funded by

613 Akouos/Eli Lilly; the site principal investigator of the sponsored Phase I/II clinical trial OTOF gene therapy with Akous/Eli

Lilly; and on the advisory board without compensation for Akous/Eli Lilly and Decibel/Akous. WJR, CN, JMH, CTS, CF,

615 EML, CL, and MAE are employees and shareholders of PacBio. The other authors have no conflicts of interest to declare.

616 **Ethics approval**

- 617 This study was approved by the institutional review board of Boston Children's Hospital (IRB P00035179 and P00031494)
- 618

619 **Consent to participate**

620 Written informed consent was obtained from all participants.

621 Consent to publish

622 Consent to publish was obtained from all participants.